Genomics technology company Nusantics announced it had raised an undisclosed amount of funds in its Series A round to enhance its research and development capability as the company plans to develop third-generation COVID-19 test kits. The company is planning to develop a test kit that can detect the coronavirus in a saliva sample as well as optimizing their test kits to be compatible with every PCR machine available in the country. “By using saliva, diagnosing COVID-19 will be more efficient, less painful for the end-user and safer for medical practitioners. Saliva will also make infectious and less-infectious detection possible,” said Nusantics CTO Revata Utama in a statement on Thursday. He went on to say that Nusantics had developed two generations of COVID-19 polymerase chain reaction (PCR) test kits that have a high sensitivity and specificity rate, which can de...